(Q37705402)

22 August 2017

1 reference

title

Sunitinib for the management of advanced renal cell carcinoma (English)

1 reference

22 August 2017

1

Bernard Escudier

1 reference

22 August 2017

1 March 2010

1 reference

Expert Review of Anticancer Therapy

22 August 2017

1 reference

22 August 2017

10

1 reference

22 August 2017

3

1 reference

22 August 2017

305-317

1 reference

Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

22 August 2017

1 reference

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

The changing pattern of kidney cancer incidence and mortality in Europe

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

21 January 2018

1 reference

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

PDGF receptors as cancer drug targets

21 January 2018

1 reference

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Sunitinib efficacy against advanced renal cell carcinoma

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial

21 January 2018

1 reference

Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

21 January 2018

1 reference

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

A phase I study of sunitinib plus bevacizumab in advanced solid tumors

21 January 2018

1 reference

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

21 January 2018

1 reference

Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy

21 January 2018

1 reference

Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.

21 January 2018

1 reference

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.

21 January 2018

1 reference

Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi

21 January 2018

1 reference

Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.

21 January 2018

1 reference

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

21 January 2018

1 reference

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma

21 January 2018

1 reference

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.10.26

1 reference

release_asqbkgcsobaw5ake6z65pjnt3m

22 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/asqbkgcsobaw5ake6z65pjnt3m

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

20214511

1 reference

PubMed ID

20214511